C4 Therapeutics CCCC Q1 2026 Earnings Narrowing Losses Drive Surprise Beat Despite Zero Revenue PAY Q1 2026 Earnings EPS Surpasses Estimates by Nearly 21 ARDX Q1 2026 Earnings EPS Misses Estimates by 142 Revenue Not Disclosed ECX Q1 2026 Earnings Significant EPS Miss Amid Challenging Operating Environment SOHOB Q2 2025 Earnings Preferred Dividend Coverage Maintained with Reported EPS of 021 LVS Q1 2026 Earnings Strong EPS Beat Amid Macau Recovery